Bio-Techne initiated with an Outperform at Scotiabank on market-leading growth

As previously reported, Scotiabank analyst Sung Ji Nam initiated coverage of Bio-Techne with an Outperform rating and $80 price target. The life science tools company has a decades-long track record of providing quality biological reagents for life sciences applications, but has also significantly expanded its addressable market over the last ten years with M&A, the analyst tells investors. The firm, which cites the company’s “industry-leading top-line growth and margin profiles,” believes Bio-Techne is one of the best positioned companies to outperform the life science tools market growth.